Kymera Therapeutics, Inc. (NASDAQ: KYMR) will present the results of its KT‑621 BroADen Phase 1b trial in patients with atopic dermatitis in a late‑breaking oral session at the American Academy of Dermatology (AAD) 2026 Annual Meeting in Denver, CO. The presentation is scheduled for Saturday, March 28, 2026, at 9:24 AM Mountain Time, and the data will be made available in the AAD resource library after the session.
KT‑621 is an oral, once‑daily STAT6 degrader that removes the transcription factor driving IL‑4/IL‑13 signaling in type‑2 inflammatory diseases. By degrading STAT6, the drug aims to provide a convenient, oral alternative to the injectable biologic dupilumab, which currently dominates the atopic dermatitis market with projected 2025 sales of roughly $16.5 billion. The Phase 1b data represent the first public evidence of KT‑621’s clinical activity and safety profile, a critical milestone that could accelerate regulatory discussions as Kymera prepares for Phase IIb trials in atopic dermatitis (BROADEN2) and asthma (BREADTH).
Chief Medical Officer Jared Gollob said, "We are honored to have our KT‑621 BroADen Phase 1b data selected for a late‑breaking oral presentation at AAD. We look forward to engaging with the dermatology community at this important forum and sharing our work to develop novel oral medicines for patients living with chronic immuno‑inflammatory diseases." The presentation will allow Kymera to gauge expert feedback and potentially refine its development strategy based on real‑world input from leading dermatologists.
The announcement follows the company’s December 8, 2025 disclosure of the Phase 1b data, and it positions Kymera to demonstrate the drug’s potential to address a large, unmet need in type‑2 inflammatory diseases. Analysts have noted the company’s strong pipeline and the growing interest in oral small‑molecule degraders, and the presentation is expected to reinforce confidence in Kymera’s strategy to bring a first‑in‑class oral therapy to market.
The event underscores Kymera’s progress in the targeted protein degradation space, a technology that enables removal of previously undruggable proteins. By showcasing early clinical results at a high‑profile dermatology forum, Kymera aims to strengthen its competitive positioning against established biologics and to attract broader attention from the medical community and potential partners.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.